tiprankstipranks
Trending News
More News >
Kaken Pharmaceutical Co Ltd (JP:4521)
:4521
Japanese Market

Kaken Pharmaceutical Co (4521) Income Statement

Compare
0 Followers

Kaken Pharmaceutical Co Income Statement

Last quarter (Q3 2025), Kaken Pharmaceutical Co's total revenue was ¥24.62B, an increase of 32.97% from the same quarter last year. In Q3, Kaken Pharmaceutical Co's net income was ¥4.89B. See Kaken Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 25Mar 24Mar 23Mar 22Mar 21
Total Revenue
¥ 94.03B¥ 72.04B¥ 72.98B¥ 76.03B¥ 74.98B
Gross Profit
¥ 58.26B¥ 38.54B¥ 39.56B¥ 41.58B¥ 40.91B
Operating Expenses
¥ 37.23B¥ 29.03B¥ 31.55B¥ 24.51B¥ 23.11B
Depreciation and Amortization
¥ 2.55B¥ 2.75B¥ 2.57B¥ 2.48B¥ 2.32B
EBITDA
¥ 22.02B¥ 12.57B¥ 10.57B¥ 16.38B¥ 20.11B
Operating Income
¥ 21.04B¥ 9.51B¥ 8.00B¥ 17.06B¥ 17.79B
Other Income/Expenses
¥ -1.60B¥ 283.00M¥ -1.18B¥ -3.18B¥ 869.00M
Pretax Income
¥ 19.43B¥ 9.80B¥ 6.82B¥ 13.88B¥ 18.66B
Net Income
¥ 13.95B¥ 8.03B¥ 5.44B¥ 9.55B¥ 13.40B
Per Share Metrics
Basic EPS
¥ 365.42¥ 212.66¥ 144.79¥ 251.44¥ 347.37
Diluted EPS
¥ 365.42¥ 212.66¥ 144.79¥ 251.44¥ 347.37
Weighted Average Shares Outstanding
38.16M 37.74M 37.57M 37.98M 38.59M
Weighted Average Shares Outstanding (Diluted)
38.16M 37.74M 37.57M 37.98M 38.59M
Currency in JPY

Kaken Pharmaceutical Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis